Brief: Alzamend Neuro Submits IND Application For A Phase III Clinical Trial In Major Depressive Disorder Patients

Alzamend Neuro

23/10/2023 14:04

Oct 23 (Reuters) - Alzamend Neuro Inc  ALZN.O :
    * ALZAMEND NEURO SUBMITS IND APPLICATION FOR A PHASE IIA
CLINICAL
TRIAL IN MAJOR DEPRESSIVE DISORDER PATIENTS OF ITS
NEXT-GENERATION LITHIUM THERAPEUTIC DRUG CANDIDATE AL001
    * ALZAMEND NEURO INC - SAFETY ASPECTS OF AL001 DEVELOPMENT
MAY
QUALIFY FOR A 505(B)(2) NDA PATHWAY FOR FDA APPROVAL

Source text for Eikon:  ID:nBw6x1ygha 
Further company coverage:  ALZN.O 

 ((Reuters.Briefs@thomsonreuters.com;))